FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367175027> ?p ?o ?g. }

• W4367175027 endingPage "3875" @default.
• W4367175027 startingPage "3862" @default.
• W4367175027 abstract "Ravulizumab demonstrated efficacy and an acceptable safety profile versus placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. We report an interim analysis of the ongoing open-label extension (OLE) designed to evaluate long-term treatment effects.Following completion of the 26-week RCP, patients could enter the OLE; patients who received ravulizumab in the RCP continued the drug; patients who previously received placebo switched to ravulizumab. Patients receive body-weight-based maintenance dosing of ravulizumab every 8 weeks. Efficacy endpoints up to 60 weeks included Myasthenia Gravis-Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores, with least-squares (LS) mean change and 95% confidence intervals (95% CI) reported.Long-term efficacy and safety in the OLE were analyzed in 161 and 169 patients, respectively. Improvements in all scores were maintained through 60 weeks in patients who received ravulizumab during the RCP; LS mean change from RCP baseline in MG-ADL score was - 4.0 (95% CI: - 4.8, - 3.1; p < 0.0001). Rapid (within 2 weeks) and sustained improvements occurred in patients previously receiving placebo; LS mean change in MG-ADL score from OLE baseline to Week 60 was - 1.7 (95% CI: - 2.7, - 0.8; p = 0.0007). Similar trends were seen in QMG scores. Ravulizumab treatment was associated with a decreased rate of clinical deterioration events compared with placebo. Ravulizumab was well tolerated; no meningococcal infections were reported.Findings support the sustained efficacy and long-term safety of ravulizumab, administered every 8 weeks, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.gov identifier: NCT03920293; EudraCT: 2018-003243-39." @default.
• W4367175027 created "2023-04-28" @default.
• W4367175027 creator A5000263337 @default.
• W4367175027 creator A5015861848 @default.
• W4367175027 creator A5032850040 @default.
• W4367175027 creator A5036372932 @default.
• W4367175027 creator A5036542525 @default.
• W4367175027 creator A5036681718 @default.
• W4367175027 creator A5065638265 @default.
• W4367175027 creator A5068616089 @default.
• W4367175027 creator A5073378507 @default.
• W4367175027 date "2023-04-27" @default.
• W4367175027 modified "2023-10-14" @default.
• W4367175027 title "Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension" @default.
• W4367175027 cites W1527112336 @default.
• W4367175027 cites W1998602672 @default.
• W4367175027 cites W2017235356 @default.
• W4367175027 cites W2023377972 @default.
• W4367175027 cites W2066571580 @default.
• W4367175027 cites W2089117937 @default.
• W4367175027 cites W2092722444 @default.
• W4367175027 cites W2130696459 @default.
• W4367175027 cites W2132605328 @default.
• W4367175027 cites W2137544340 @default.
• W4367175027 cites W2142409409 @default.
• W4367175027 cites W2460848699 @default.
• W4367175027 cites W2461303519 @default.
• W4367175027 cites W2473388648 @default.
• W4367175027 cites W2555200991 @default.
• W4367175027 cites W2766784006 @default.
• W4367175027 cites W2797057269 @default.
• W4367175027 cites W2903198260 @default.
• W4367175027 cites W2912901461 @default.
• W4367175027 cites W2972066878 @default.
• W4367175027 cites W2991961334 @default.
• W4367175027 cites W2995690790 @default.
• W4367175027 cites W3009429865 @default.
• W4367175027 cites W3013095455 @default.
• W4367175027 cites W3026834368 @default.
• W4367175027 cites W3041450548 @default.
• W4367175027 cites W3082547339 @default.
• W4367175027 cites W3106936335 @default.
• W4367175027 cites W3113204637 @default.
• W4367175027 cites W3129249804 @default.
• W4367175027 cites W3165199917 @default.
• W4367175027 cites W3165482046 @default.
• W4367175027 cites W3213765021 @default.
• W4367175027 cites W4211188347 @default.
• W4367175027 cites W4224989731 @default.
• W4367175027 cites W4226521495 @default.
• W4367175027 cites W4246582376 @default.
• W4367175027 cites W4294992089 @default.
• W4367175027 cites W4323652072 @default.
• W4367175027 cites W4327923084 @default.
• W4367175027 cites W4367175027 @default.
• W4367175027 cites W4380204143 @default.
• W4367175027 doi "https://doi.org/10.1007/s00415-023-11699-x" @default.
• W4367175027 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37103755" @default.
• W4367175027 hasPublicationYear "2023" @default.
• W4367175027 type Work @default.
• W4367175027 citedByCount "4" @default.
• W4367175027 countsByYear W43671750272023 @default.
• W4367175027 crossrefType "journal-article" @default.
• W4367175027 hasAuthorship W4367175027A5000263337 @default.
• W4367175027 hasAuthorship W4367175027A5015861848 @default.
• W4367175027 hasAuthorship W4367175027A5032850040 @default.
• W4367175027 hasAuthorship W4367175027A5036372932 @default.
• W4367175027 hasAuthorship W4367175027A5036542525 @default.
• W4367175027 hasAuthorship W4367175027A5036681718 @default.
• W4367175027 hasAuthorship W4367175027A5065638265 @default.
• W4367175027 hasAuthorship W4367175027A5068616089 @default.
• W4367175027 hasAuthorship W4367175027A5073378507 @default.
• W4367175027 hasBestOaLocation W43671750271 @default.
• W4367175027 hasConcept C126322002 @default.
• W4367175027 hasConcept C142724271 @default.
• W4367175027 hasConcept C204787440 @default.
• W4367175027 hasConcept C27081682 @default.
• W4367175027 hasConcept C2777288759 @default.
• W4367175027 hasConcept C2778105408 @default.
• W4367175027 hasConcept C535046627 @default.
• W4367175027 hasConcept C61943457 @default.
• W4367175027 hasConcept C71924100 @default.
• W4367175027 hasConceptScore W4367175027C126322002 @default.
• W4367175027 hasConceptScore W4367175027C142724271 @default.
• W4367175027 hasConceptScore W4367175027C204787440 @default.
• W4367175027 hasConceptScore W4367175027C27081682 @default.
• W4367175027 hasConceptScore W4367175027C2777288759 @default.
• W4367175027 hasConceptScore W4367175027C2778105408 @default.
• W4367175027 hasConceptScore W4367175027C535046627 @default.
• W4367175027 hasConceptScore W4367175027C61943457 @default.
• W4367175027 hasConceptScore W4367175027C71924100 @default.
• W4367175027 hasFunder F4320321526 @default.
• W4367175027 hasIssue "8" @default.
• W4367175027 hasLocation W43671750271 @default.
• W4367175027 hasLocation W43671750272 @default.
• W4367175027 hasLocation W43671750273 @default.
• W4367175027 hasOpenAccess W4367175027 @default.
• W4367175027 hasPrimaryLocation W43671750271 @default.

• next